Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ophthalmic Insert
Insert · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ophthalmic Insert | DRUG | Travoprost, 0.32 mg |
Inclusion Criteria: * Had prior bilateral treatment and completion, through a minimum of week 12, of the OTX-16-002 trial * Are informed of the nature of the study and subject is able to comply with study requirements and visit schedule for one year * Have provided written informed consent, approve...
Insert is an investigational ophthalmic insert being developed for open angle glaucoma and ocular hypertension. It is designed to be placed in the eye to deliver sustained-release travoprost, a small molecule therapy. It is not yet approved and remains in clinical development.
Insert is being developed by Ocular Therapeutix, Inc., which trades on the Nasdaq under the ticker OCUL. The company is the sponsor of the clinical program evaluating the insert for open angle glaucoma and ocular hypertension.
Insert is in Phase 3 clinical development. A Phase 3 study evaluating the long-term safety of the sustained-release travoprost intracanalicular insert has been completed. The program remains investigational and has not been approved for commercial use.
Insert has been studied in one completed Phase 3 trial, NCT04061044, titled A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert. The trial enrolled 40 participants in the United States and evaluated patients with open angle glaucoma and ocular hypertension.
Yes, Insert is also known as Ophthalmic Insert. Both names refer to the same investigational sustained-release travoprost intracanalicular insert developed by Ocular Therapeutix for open angle glaucoma and ocular hypertension.